NDASUBCUTANEOUSSOLUTION
Approved
Aug 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
5/8 — Partial
DAWNZERA (AUTOINJECTOR) (donidalorsen) by Ionis Pharmaceuticals is aso‑galnac conjugate that causes ribonuclease h1 (rnase h1)‑mediated degradation of pkk mrna through binding to pkk mrna, which results in reduced production of pkk protein. First approved in 2025.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAWNZERA is a subcutaneous antisense oligonucleotide (ASO) conjugate that degrades prekallikrein (PKK) mRNA, reducing bradykinin production and angioedema attacks in hereditary angioedema (HAE) patients. It represents a novel mechanism targeting the contact system pathway in rare genetic disease. The autoinjector formulation enables patient self-administration and improved convenience.
Growth8.6 years to LOE
Recently approved growth-stage RNA therapeutic with no current linked positions, indicating early commercialization phase requiring rapid team expansion.
Mechanism of Action
ASO‑GalNAc conjugate that causes ribonuclease H1 (RNase H1)‑mediated degradation of PKK mRNA through binding to PKK mRNA, which results in reduced production of PKK protein. PKK is a pro‑enzyme for plasma kallikrein, which results in the release of bradykinin, a potent vasodilator causing swelling…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Donidalorsen Treatment in Children With Hereditary Angioedema
Started Apr 2026
20 enrolled
Hereditary Angioedema (HAE)
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Started Jul 2022
154 enrolled
Hereditary Angioedema
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
Started Dec 2021
91 enrolled
Hereditary Angioedema
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
Started Mar 2020
20 enrolled
Hereditary Angioedema
A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema
Started Jan 2020
23 enrolled
Hereditary Angioedema
Worked on DAWNZERA (AUTOINJECTOR) at Ionis Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.